Back

Validation of the cardiac damage classification and additional effects of albumin levels in a large cohort of patients undergoing transcatheter aortic valve replacement

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: TAVR outcomes: the future is here Aortic Valve Intervention ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Anat Berkovitch

Chaim Sheba Medical Center, Ramat Gan (Israel)

5 More presentations in this session

Presentation thumbnail
Mortality of surgical redo aortic valve replacement versus transcatheter aortic valve-in-valve implantation in patients with degenerated aortic bioprosthesis: a meta-analysis.
Doctor A. Pardo Sanz (Madrid, ES)
Abstract Slides
Presentation thumbnail
Incidence, risk factors and impact of readmission for heart failure after successful transcatheter aortic valve replacement
Doctor P. Guedeney (Paris, FR)
Abstract Slides
Presentation thumbnail
Timing and associated predictors of onset of new conduction disturbances requiring permanent pacemaker implantation after transcatheter aortic valve implantation
Miss N. Kooistra (Utrecht, NL)
Abstract
Presentation thumbnail
High H2FPEF score is an independent predictor of adverse outcome in patients with severe aortic stenosis and preserved ejection fraction undergoing TAVR
Doctor S. Ludwig (Hamburg, DE)
Abstract Slides
Presentation thumbnail
Stroke after transcatheter aortic valve implantation: an unpredictable risk?
Mr G. Bosbach (Duesseldorf, DE)
Abstract Slides

Access the full session

Session thumbnail
TAVR outcomes: the future is here

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Presentation
Correlations with anatomic specimens
thumbnail
Congress Presentation
Percutaneous devices for valve repair and replacement
thumbnail
Congress Session
Failing valves and beyond

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources